Antibody-Mediated Rejection Prevention Market By Component (HLA & DSA Testing, Maintenance Immunosuppression, Desensitization Therapy, Plasma Exchange & IVIG, Transplant Biopsy, dd-cfDNA Testing, Targeted Biologics); By Organ Transplant Type (Kidney Transplants, Heart Transplants, Lung Transplants, Liver Transplants, Other Solid-Organ Transplants); By End User (Hospitals & Transplant Centers, Histocompatibility Laboratories, Specialty Diagnostic Laboratories, Apheresis & Infusion Centers, Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Antibody-Mediated Rejection Prevention Market: Rising Transplant Volumes, Diagnostic Surveillance, and Targeted Biologics Reshape Graft Protection

The Global Antibody-Mediated Rejection Prevention Market was valued at USD 215.00 billion in 2025 and is projected to reach USD 393.03 billion by 2032, expanding at a 9.0% CAGR during the forecast period, according to analysis by Strategic Market Research.

 

The antibody-mediated rejection prevention market includes HLA compatibility testing, donor-specific antibody surveillance, maintenance immunosuppression, pre-transplant desensitization, therapeutic plasma exchange, intravenous immunoglobulin, transplant biopsy, molecular diagnostics, and targeted therapies used to prevent or limit antibody-related damage to transplanted organs.

 

Commercial demand begins before transplantation and continues throughout the functioning life of the graft. Every transplant adds a long-term user of immunosuppressive medicines, laboratory monitoring, specialist care, and rejection surveillance. When antibody-mediated rejection develops, spending rises through biopsy, hospitalization, apheresis, IVIG, corticosteroids, and additional off-label immune therapies.

 

Record Transplant Activity Expands the Prevention Population

A record 173,727 solid-organ transplants were performed worldwide in 2024, approximately 2% more than in 2023. Global activity included 47,180 deceased donors and averaged nearly 20 organ transplants every hour. Kidney transplantation remained the largest organ category, giving renal AMR prevention the broadest patient and revenue base.

The United States completed 49,064 organ transplants in 2025. Kidney procedures represented 27,573 transplants, or approximately 56% of national transplant activity. These included 21,052 deceased-donor and 6,521 living-donor kidney transplants. More than 90,000 Americans continued to wait for a kidney, maintaining demand for compatibility testing, kidney-paired donation, and desensitization.

India reported 18,911 organ transplants in 2024, compared with 4,990 procedures in 2013. Kidney transplantation represented 13,476 procedures, including 11,558 living-donor and 1,918 deceased-donor transplants. The expansion is increasing demand for HLA laboratories, transplant pathology, immunosuppressants, apheresis capacity, and long-term monitoring.

 

AMR Incidence Creates a Disproportionately High Economic Burden

The American Kidney Fund estimates that AMR affects fewer than one in ten kidney recipients, but it remains a leading cause of graft loss. Published studies report acute AMR incidence ranging from approximately 1% to 15%, while chronic AMR affects around 8% to 20% of kidney recipients in different populations.

Risk is substantially higher among sensitized patients transplanted across HLA incompatibilities. A meta-analysis of desensitized, highly HLA-sensitized kidney recipients reported an AMR rate of 37.7%, compared with an acute cellular rejection rate of 15.1%. Transplant glomerulopathy was identified in 21.9% of recipients. Despite this risk, pooled patient survival remained 94.2% at one year and 88.9% at five years, showing why transplant centers continue to invest in desensitization and intensive monitoring.

AMR can progress despite therapy and is strongly associated with late graft failure. Biogen estimates that approximately 23,000 U.S. kidney recipients are living with different forms of AMR. The population includes active, chronic active, and late rejection rather than only newly diagnosed annual cases.

The financial burden extends beyond the initial rejection episode. A failed kidney graft can return a patient to long-term dialysis, generate another transplant evaluation, and create demand for a second scarce donor organ. Treatments that preserve graft function can therefore produce savings beyond their direct drug or procedure costs.

 

Compatibility and DSA Testing Form the First Diagnostic Layer

AMR prevention begins with identifying pre-existing antibodies before transplantation. Histocompatibility laboratories use HLA antibody screening, Luminex single-antigen bead assays, complement-dependent cytotoxicity crossmatching, and flow-cytometry crossmatching to determine whether the recipient is likely to attack a prospective donor organ.

Highly sensitized candidates can carry antibodies against a broad share of the donor population after pregnancy, blood transfusion, or a previous transplant. These patients may wait much longer for a compatible organ or require kidney-paired donation and desensitization.

Single-antigen bead assays identify the HLA targets of donor-specific antibodies and report their signal through mean fluorescence intensity. Complement-binding tests such as C1q assays can help distinguish DSAs more likely to activate inflammatory tissue injury. Crossmatching then tests whether recipient serum reacts directly against donor cells.

Testing is repeated because antibody status can change. A recipient may be assessed during transplant evaluation, after a donor offer, during early post-transplant surveillance, after a reduction in immunosuppression, and whenever graft dysfunction appears. Public registries do not provide a verified consolidated worldwide count of DSA assays, so exact annual test-volume estimates should be treated as modeled figures rather than recorded activity.

 

Diagnosis Requires Three Banff Evidence Categories

A positive DSA blood test does not independently confirm AMR. The Banff framework integrates three evidence categories:

• Histologic injury: Kidney biopsy must show tissue damage consistent with antibody activity, commonly microvascular inflammation involving glomerulitis and peritubular capillaritis.

• Antibody–endothelium interaction: Evidence may include C4d deposition in peritubular capillaries, moderate microvascular inflammation, or validated molecular transcripts associated with endothelial injury.

• Serologic evidence: Circulating donor-specific HLA or relevant non-HLA antibodies must be identified, although some newer Banff phenotypes account for cases without detectable DSA.

The Banff 2022 consensus introduced “probable AMR” for DSA-positive patients with some AMR-associated histologic changes but insufficient evidence for definitive AMR. It also recognized microvascular inflammation that is both DSA-negative and C4d-negative as a separate phenotype requiring further investigation.

A study of 1,891 kidney recipients evaluated 566 biopsies taken from 178 DSA-positive transplants. Probable AMR was present in 12.4% of first DSA-positive biopsies, demonstrating that a meaningful group falls between no rejection and full Banff-defined AMR.

Kidney biopsy remains the confirmation standard because serum creatinine, eGFR, DSA, and donor-derived cell-free DNA cannot independently distinguish AMR from cellular rejection, infection, recurrent kidney disease, or immunosuppressant toxicity. The need to combine blood testing with pathology supports recurring revenue across transplant laboratories and biopsy services.

 

Donor-Derived Cell-Free DNA Adds Measurable Diagnostic Value

Donor-derived cell-free DNA detects DNA fragments released into the recipient’s blood when transplanted tissue is injured. Its short circulation time allows it to reflect active graft damage more rapidly than serum creatinine in some patients.

In the landmark DART study, a dd-cfDNA threshold of 1% produced 59% sensitivity and 85% specificity for active rejection. The positive predictive value was approximately 61%, while the negative predictive value reached 84%. At levels below 0.21%, the negative predictive value for acute rejection was approximately 95%, supporting the test’s role in ruling out active injury in low-risk cases.

Performance is stronger for antibody-mediated injury than for milder cellular rejection. One clinical evaluation reported an area under the curve of 0.82 for AMR. A dd-cfDNA threshold of 0.74% delivered 100% sensitivity, 71.8% specificity, 68.6% positive predictive value, and 100% negative predictive value for AMR in the studied cohort.

A separate prospective study identified an optimal threshold of 0.57%, which produced 53% sensitivity, 81% specificity, 58% positive predictive value, and 77% negative predictive value for active rejection. The variation across studies shows why transplant centers interpret dd-cfDNA alongside DSA, graft function, clinical risk, and biopsy rather than using one universal cutoff.

Combining DSA and dd-cfDNA improves risk stratification. DSA indicates that the recipient has antibodies capable of attacking the graft, while elevated dd-cfDNA indicates that tissue injury is occurring. This supports a layered diagnostic model in which routine chemistry triggers investigation, biomarkers refine risk, and biopsy confirms the treatment pathway.

 

Treatment Remains Multimodal and Procedure Intensive

No single approved therapy has become a universal standard for active or chronic active AMR. Treatment generally attempts to remove circulating antibodies, suppress antibody-producing cells, block inflammatory injury, and optimize maintenance immunosuppression.

Therapeutic plasma exchange and IVIG remain the most widely used combination. Plasma exchange physically removes circulating DSAs, while IVIG modulates antibody activity and may limit immune rebound. Corticosteroid pulses are frequently added when active inflammation is present.

One randomized AMR trial involving 38 kidney recipients used a standard regimen of six plasma-exchange sessions, with IVIG at 100 mg/kg after each session, followed by 2 g/kg over two days after completion of the exchange cycle. This illustrates the treatment intensity and hospital-resource use associated with a single AMR episode.

A typical course may therefore involve several apheresis visits, repeated DSA testing, IVIG infusions, laboratory monitoring, and follow-up biopsy. Session numbers can rise when antibody levels rebound or kidney function fails to improve.

 

Combination Therapy Produces Better Outcomes in Some Cohorts but Evidence Remains Uneven

A retrospective comparison found 36-month graft survival of 91.7% among patients receiving plasma exchange, IVIG, and anti-CD20 therapy, compared with 50% among patients treated with high-dose IVIG alone. The study supports combination treatment but was not large enough to establish one universal protocol.

Evidence for rituximab remains mixed. Rituximab depletes CD20-positive B cells but does not directly eliminate mature plasma cells already producing DSAs. The randomized RITUX-ERAH study added rituximab to plasma exchange, IVIG, and corticosteroids but did not demonstrate a clear one-year advantage over standard treatment alone.

In another small study, seven patients received rituximab with IVIG, but only 57% maintained graft survival at 24 months. These inconsistent results explain why rituximab remains an off-label adjunct rather than an AMR-specific standard.

Bortezomib targets antibody-producing plasma cells more directly. However, controlled evidence has not consistently demonstrated durable graft benefit, and neuropathy, cytopenia, infection, and gastrointestinal toxicity restrict broad preventive use.

Eculizumab blocks terminal complement activation and can reduce immediate antibody-driven vascular injury. Its use is concentrated in selected severe or high-risk patients because it does not eliminate DSA production and requires infection-risk management.

 

Maintenance Immunosuppression Delivers the Broadest Recurring Revenue

Every functioning solid-organ graft requires continued immunosuppression. Tacrolimus, mycophenolate, corticosteroids, induction agents, and therapeutic drug monitoring are not exclusive to AMR, but inadequate exposure or non-adherence can lead to de novo DSA formation.

The maintenance segment is commercially broader than the treated-AMR population because it covers nearly every transplant recipient. Growth is linked to the cumulative number of people living with functioning grafts rather than annual rejection cases alone.

Generic competition limits revenue expansion for established oral immunosuppressants. Higher-value opportunities are concentrated in adherence services, therapeutic drug monitoring, lower-toxicity maintenance regimens, and treatments that prevent antibody development without materially increasing infection or malignancy risk.

 

Felzartamab Leads the Active-AMR Pipeline

Felzartamab is an investigational anti-CD38 monoclonal antibody designed to deplete mature plasma cells and reduce natural-killer-cell activity involved in microvascular inflammation.

Its randomized Phase 2 trial enrolled 22 kidney recipients, equally divided between felzartamab and placebo. More than 80% of felzartamab-treated patients achieved biopsy-confirmed AMR resolution at week 24, compared with approximately 20% in the placebo group. Molecular follow-up found recurrent AMR activity in 8 of 9 initial molecular responders after treatment ended, suggesting that repeat or maintenance therapy may be needed.

The Phase 3 TRANSCEND study targets approximately 120 participants with late AMR. Its primary endpoint is biopsy-confirmed histologic resolution at week 24, with a readout expected in 2027.

 

Imlifidase Creates a Rapid Desensitization Segment

Imlifidase is an IgG-degrading enzyme that can rapidly cleave circulating antibodies and convert a positive crossmatch before transplantation. Its role is concentrated in highly sensitized kidney candidates rather than routine chronic-AMR treatment.

The FDA accepted the imlifidase biologics license application in February 2026 and assigned a December 19, 2026 action date. It is already conditionally approved in Europe for selected highly sensitized adults with a positive crossmatch against an available deceased donor.

Imlifidase can reduce circulating IgG by more than 95% within two to six hours, creating a short window in which transplantation can proceed. This rapid effect differentiates it from repeated plasma exchange and slower B-cell-directed therapy.

 

Complement and IL-6 Programs Broaden Pipeline Competition

Sanofi’s riliprubart inhibits activated C1s in the classical complement pathway. Its ongoing Phase 2 program includes patients at risk of AMR and patients with active AMR. The FDA granted orphan-drug designation in June 2025.

The INTERCEPT trial is evaluating tocilizumab in 50 kidney recipients with chronic active AMR. Patients are divided between 25 receiving tocilizumab plus standard care and 25 receiving standard care alone for 24 months. The focus on eGFR decline reflects the need to show durable graft preservation rather than only short-term antibody reduction.

Takeda’s mezagitamab is adding another anti-CD38 candidate to the pipeline. The planned Phase 2 study evaluates safety and activity in adults with late kidney-transplant AMR.

 

Kidney Transplants Dominate Application Demand

Kidney transplantation represents the leading organ segment because it accounts for the greatest number of solid-organ procedures and has the most developed AMR diagnostic and treatment pathway.

Heart and lung transplantation represent smaller but intensive segments. These recipients may undergo frequent early surveillance because graft deterioration can progress rapidly. Liver AMR remains a narrower segment because diagnostic criteria and treatment practices are less uniform.

 

Transplant Hospitals Control Most End-User Spending

Academic medical centers and specialist transplant hospitals account for most AMR-related treatment, biopsy, apheresis, and infusion spending. Histocompatibility laboratories capture pre-transplant HLA testing and crossmatching demand, while pathology laboratories perform biopsy assessment.

Specialty diagnostic laboratories are gaining revenue through DSA characterization, dd-cfDNA, and molecular profiling. New pharmaceutical adoption will remain controlled by transplant-center protocols because treatment selection depends on integrated clinical, biopsy, antibody, and biomarker evidence.

 

Regional Opportunity Follows Transplant Infrastructure

North America has a strong commercial position because the United States combines more than 49,000 annual organ transplants, advanced HLA laboratories, apheresis capacity, molecular surveillance, and several late-stage AMR trials.

Europe combines mature transplant networks with existing access to imlifidase-based desensitization, although reimbursement and treatment protocols differ by country. Asia-Pacific growth is supported by rising transplant activity, including India’s 18,911 procedures in 2024, but access to advanced biomarkers and premium biologics remains concentrated in major urban transplant centers.

 

Market Outlook

Near-term revenue will remain concentrated in maintenance immunosuppression, HLA and DSA testing, kidney biopsy, plasma exchange, IVIG, and hospital-based care. These categories serve the expanding population living with transplanted organs and do not depend on approval of one investigational product.

Pipeline agents are beginning to create a defined high-value pharmaceutical segment. Felzartamab has produced strong biopsy-response data but may require continued treatment. Imlifidase is approaching a U.S. regulatory decision in desensitization, while riliprubart, tocilizumab, and mezagitamab target complement activation, inflammatory signaling, and plasma-cell biology.

Commercial success will depend on more than DSA reduction or short-term biopsy improvement. Developers must demonstrate slower eGFR decline, fewer hospitalizations, reduced plasma-exchange and IVIG use, lower graft-loss rates, and longer functioning graft life. Therapies that achieve these outcomes can shift AMR care from repeated rescue procedures toward planned, biomarker-guided graft protection.

 

Antibody-Mediated Rejection Prevention Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 215.00 Billion
Revenue Forecast in 2032	USD 393.03 Billion
Overall Growth Rate	CAGR of 9.0% (2026–2032)
Base Year for Estimation	2025
Historical Data	2019–2024
Unit	USD Billion, CAGR (2026–2032)
Segmentation	By Component, By Organ Transplant Type, By End User, By Geography
By Component	HLA & DSA Testing, Maintenance Immunosuppression, Desensitization Therapy, Plasma Exchange & IVIG, Transplant Biopsy, Donor-Derived Cell-Free DNA Testing, Targeted Biologics
By Organ Transplant Type	Kidney Transplants, Heart Transplants, Lung Transplants, Liver Transplants, Other Solid-Organ Transplants
By End User	Hospitals & Transplant Centers, Histocompatibility Laboratories, Specialty Diagnostic Laboratories, Apheresis & Infusion Centers, Research Institutions
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising global solid-organ transplant volumes Growing adoption of HLA compatibility testing, donor-specific antibody surveillance, and donor-derived cell-free DNA monitoring Expanding use of desensitization protocols, plasma exchange, IVIG, and targeted biologics to preserve graft function Greater clinical focus on preventing chronic antibody-mediated injury and reducing graft-loss risk
Customization Option	Available upon request